Posted in | Nanomedicine | Nanobusiness

Liquidia Technologies Announces Frank J. Malinoski as its New Chief Medical Officer

Liquidia Technologies, a privately held biopharmaceutical company developing particle-based vaccines and therapeutics, announced today that Frank J. Malinoski, M.D., Ph.D., has joined the company as Chief Medical Officer.

Dr. Malinoski has more than 20 years of executive experience in the biotech and pharmaceutical industries, including work in clinical development, regulatory evaluation and post-approval oversight for numerous vaccines and immunotherapy products. In his position, Dr. Malinoski will be responsible for clinical strategy and regulatory affairs across Liquidia's product platform.

"We are extremely pleased to have Frank join our leadership team," said Neal Fowler, Liquidia's Chief Executive Officer. "Frank's scientific expertise and impressive track record developing and commercializing successful vaccines will be invaluable as we advance our initial vaccine candidate through clinical trials and expand our pipeline of vaccine and therapeutic products."

Dr. Malinoski brings to Liquidia an extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. He has held senior positions in clinical research, business development and medical affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies. Dr. Malinoski began his career in the military, serving in clinical research and development of vaccines against infectious disease threats. Dr. Malinoski received his B.A. from Colby College, his M.D. from Albany Medical College and his Ph.D. in microbiology from Rutgers University.


Posted February 19th, 2010

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback